{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tyrosine
to a specific field?
Status:
Investigational
Source:
INN:cofetuzumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03524261: Phase 2 Interventional Withdrawn Advanced Breast Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04189614: Phase 1 Interventional Active, not recruiting Cancer
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:timigutuzumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03780972: Phase 1 Interventional Completed Rhegmatogenous Retinal Detachment - Macula Off
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04456621: Not Applicable Interventional Completed Local Control Rate
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03014076: Phase 1 Interventional Completed Breastcancer
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ozureprubart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
